BioAdaptives

BioAdaptives Net Debt

The Net Debt of BioAdaptives (BDPT) as of Oct 26, 2026 is 225,983.00 USD. In the previous year, Net Debt was 205,626.00 USD — a change of 9.90% (higher).

Net Debt

225,983.00USD

YoY

9.90%

Last updated:

Net Debt of BioAdaptives is 2025 225,983.00 USD. Net Debt of BioAdaptives was 2024 205,626.00 USD. It decreases by 9.90% higher compared to the previous year.

The BioAdaptives Net Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Debt
Date
Net Debt
Jan 1, 2018
27,609.00 USD
Jan 1, 2019
357,026.00 USD
Jan 1, 2020
477,920.00 USD
Jan 1, 2021
353,706.00 USD
Jan 1, 2022
366,592.00 USD
Jan 1, 2023
268,402.00 USD
Jan 1, 2024
205,626.00 USD
Jan 1, 2025
225,983.00 USD
The BioAdaptives Net Debt history
YEARNet DebtYoY
225,983.00USD+9.90%
205,626.00USD-23.39%
268,402.00USD-26.78%
366,592.00USD+3.64%
353,706.00USD-25.99%
477,920.00USD+33.86%
357,026.00USD+1,193.15%
27,609.00USD-874.88%
-3,563.00USD-68.42%
-11,283.00USD+127.34%
-4,963.00USD-86.10%
-35,706.00USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

BioAdaptives Stock analysis

What does BioAdaptives do? BioAdaptives, Inc. generates revenue through the sale of health and wellness products including dietary supplements, specialty food items, and devices that optimize bioelectromagnetic availability. The company markets PrimiCell and PrimiLive under a product agreement with Ferris Holding, Inc., targeting consumers seeking cognitive enhancement, fatigue reduction, and anti-aging solutions. PrimiTrim serves the weight control segment, while Equine Regen and Equine Regen Plus are in advanced testing for veterinary use. The firm also develops a dog product, expanding its wellness offerings across human and animal health markets. Ferris Holding, Inc. provides the intellectual property and products that BioAdaptives markets, including PrimiCell and PrimiLive, which are positioned for cognition, focus, and emotional wellness. The company's advanced-stage products Equine Regen and Equine Regen Plus cater to the veterinary segment, with PrimiTrim addressing weight management needs. BioAdaptives' product portfolio spans nutraceuticals, devices, and specialty foods designed to improve physical and emotional wellness across multiple consumer segments. BioAdaptives focuses on selling devices and nutraceuticals that target cognitive performance, fatigue reduction, and anti-aging, with PrimiCell and PrimiLive as key products under the Ferris agreement. The company's weight control solution PrimiTrim appeals to consumers seeking wellness through diet, while Equine Regen and Equine Regen Plus target animal health providers. The firm's development of a dog product further diversifies its offerings in the wellness market. BioAdaptives is one of the most popular companies on Eulerpool.

Frequently Asked Questions about BioAdaptives stock

Net Debt of BioAdaptives is 225,983.00 USD in 2025.

Net Debt of BioAdaptives changed from 205,626.00 USD to 225,983.00 USD, representing a 9.90% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Debt BioAdaptives since 2006 – with annual values, charts, and detailed analysis.

Net debt is total debt minus cash and cash equivalents. It shows the actual debt burden after accounting for available liquid resources.

Net Debt's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Net Debt's BioAdaptives historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — BioAdaptives

All Key Metrics — BioAdaptives